IASO Bio reports 90 percent response rate for CAR T therapy
Biotechnology developer IASO Bio announced a 90 percent objective response rate from first in human clinical trials evaluating its IASO206 in vivo CAR T candidate for multiple myeloma
IASO Biotechnology reported promising results from a Phase 1 clinical trial on IASO206, an intravenous CAR-T cell therapy targeting BCMA for patients with relapsed/refractory multiple myeloma (R/R MM). The study, presented at the 2026 International Myeloma Society (IMS) Annual Meeting, demonstrated an impressive 90% objective response rate (ORR) and 90% minimal residual disease (MRD) negativity rate, with the latter reaching 100% in the high-dose cohort.
One patient in the low-dose cohort achieved a very good partial response (VGPR), while all infusion-related reactions were mild and resolved quickly. The trial enrolled 10 patients who had exhausted at least two therapy lines, with 70% of them having high-risk and 70% of them having ultra-high-risk cytogenetic features. These encouraging results suggest IASO206's potential as a viable treatment for high-risk, treatment-resistant R/R MM patients.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
